Brokerages Expect Aerpio Pharmaceuticals, Inc. (NYSE:ARPO) to Post -$0.12 EPS

Share on StockTwits

Equities research analysts expect Aerpio Pharmaceuticals, Inc. (NYSE:ARPO) to post earnings of ($0.12) per share for the current quarter, according to Zacks. Zero analysts have made estimates for Aerpio Pharmaceuticals’ earnings. Aerpio Pharmaceuticals posted earnings of ($0.21) per share in the same quarter last year, which would indicate a positive year over year growth rate of 42.9%. The business is expected to report its next earnings report on Tuesday, March 3rd.

According to Zacks, analysts expect that Aerpio Pharmaceuticals will report full year earnings of ($0.58) per share for the current fiscal year. For the next year, analysts expect that the firm will report earnings of ($0.41) per share. Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research firms that cover Aerpio Pharmaceuticals.

Shares of ARPO stock remained flat at $$0.69 during midday trading on Friday. 104,800 shares of the stock were exchanged, compared to its average volume of 341,334. The business’s fifty day moving average price is $0.65 and its 200 day moving average price is $0.62. Aerpio Pharmaceuticals has a 52 week low of $0.45 and a 52 week high of $4.25.

About Aerpio Pharmaceuticals

Aerpio Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing treatments for ocular diseases. The company's lead product candidate is AKB-9778, a small molecule activator of the Tie2 pathway, which completed the Phase 2a clinical trial for the treatment of diabetic retinopathy.

Further Reading: Dividend Achievers

Get a free copy of the Zacks research report on Aerpio Pharmaceuticals (ARPO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Aerpio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerpio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.